The efficacy of strategies used to minimise or prevent Cisplatin-induced ototoxicity in patients

South African Journal of Oncology

ARTICLE

Zenzo S. Chakara¹  Lebogang Ramma¹ 

[1] Department of Health and Rehabilitation, Faculty of Health Sciences, University of Cape Town

关键词: cisplatin;    cancer;    ototoxicity;    hearing loss;    chemotherapy;   

DOI  :  10.4102/sajo.v3i0.54

学科分类：工业工程学

来源: AOSIS

【 摘 要 】

Background:  Hearing loss is a major side effect of cisplatin-based chemotherapy. With a large burden of cancer in developing countries, an evidence-based approach to prevention of cisplatin-induced hearing loss (ototoxicity) is pertinent. Aim:  This study aimed to evaluate the efficacy of treatment modifications currently being implemented to prevent or minimise ototoxicity during cisplatin-based chemotherapy. Setting:  A retrospective medical folder review design was employed. Purposive sampling was used to select medical folders of adult patients who were undergoing cisplatin-based chemotherapy at Groote Schuur Hospital between January 2011 and December 2016. Method:  Demographic, cisplatin chemotherapy treatment and audiometric data were extracted from patients’ records. The Common Terminology Criteria of Adverse Events version 4 (CTCAE v4) grading scale was used to determine ototoxicity and grade severity of hearing loss. Data were analysed using R, a software environment for statistical computing. Results:  Fifty-eight medical folders were included in the study (median age = 43 years; range: 18–75 years; 36 male, 22 female; average length of treatment: 13.45 weeks). Three treatment modifications were used: Dose reduction, switching drugs and continuing with the same drug. Common Terminology Criteria of Adverse Events version 4 grading scale revealed ototoxicity in 75 % of the patients who switched drugs, 50% of the patients with reduced dose and 56 % of the patients who were continued on the same drug. There was no statistically significant association between treatment modifications and incidence of ototoxicity. Conclusion:  Most patients experienced cisplatin-induced ototoxicity despite treatment modifications. There was no statistically significant association between any of the strategies implemented and incidence of hearing loss.

【 授权许可】

CC BY